AMALY — SHARIAH COMPLIANCE REPORT
==================================
Symbol: ARMP
Report Date: 2026-04-06
Full Report: https://amaly.io/stock/ARMP

EXECUTIVE SUMMARY
------------------
Compliance Status: NON_COMPLIANT
Quality Rating: B
Description: This report evaluates Armata Pharmaceuticals, Inc. (ARMP) for Shariah compliance across financial, business activity, and governance dimensions. The analysis reveals significant challenges in financial screening due to high debt and interest income ratios, while business activities in biotechnology appear permissible. Overall, the company does not meet key Shariah thresholds, leading to a non-compliant status. Investors are advised to consider purification requirements and monitor financial improvements. Alternative compliant investments in healthcare are recommended.

Primary Compliance Concerns:
- Debt ratio: 126.27% exceeds AAOIFI's 30% threshold and others at 33%
- Interest income ratio: 454.58% exceeds the 5% limit across all standards

Purification Requirement: 454.58%
Index Inclusion: Not included in S&P Dow Jones Shariah Indices, MSCI Islamic Indices, FTSE Shariah Indices, or Dow Jones Islamic Market (DJIM)

KEY FINANCIAL METRICS
----------------------
Debt Ratio: 126.3%
Liquidity Ratio: 11.0%
Interest Income Ratio: 454.6%
Purification Required: 0.00%

INDEX INCLUSION STATUS
-----------------------
S&P Shariah: EXCLUDED
MSCI Islamic: EXCLUDED
DJIM: EXCLUDED
FTSE Shariah: EXCLUDED
Total: 0 of 4
Last Verified: 2025-12-31

REPORTING PERIOD
-----------------
Latest Annual Report: FY 2025
Latest Quarterly Data: Q4 2025
Trend Period: FY 2020 to FY 2025
Data Retrieved: 2026-02-27T00:00:00Z

---
Full interactive report: https://amaly.io/stock/ARMP
Provided by Amaly (https://amaly.io) — Shariah Compliant Stock Screener
Disclaimer: This data is for informational purposes only and does not constitute financial or religious advice.